---
schema_version: "secwatch.filing_event.v1"
accession: "0001933414-24-000015"
form_type: "8-K"
ticker: "MLYS"
cik: "0001933414"
company_name: "Mineralys Therapeutics, Inc."
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T07:15:37.002202+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Mineralys Q1 net loss $31.5M; cash $338.6M; Advance-HTN topline due Q4 2024

## Summary
- Net loss of $31.5M for Q1 2024, up from $12.6M in Q1 2023; R&D expenses $30.8M.
- Cash, equivalents and investments $338.6M as of March 31, 2024; private placement net ~$116M in Q1.
- Advance-HTN pivotal trial topline data expected in Q4 2024.
- Launch-HTN Phase 3 trial topline data anticipated in 2H 2025.
- Explore-CKD Phase 2 topline data expected Q4 2024 to Q1 2025.

## SEC filing metadata
- accession: 0001933414-24-000015
- form_type: 8-K
- ticker: MLYS
- cik: 0001933414
- company_name: Mineralys Therapeutics, Inc.
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1933414/000193341424000015/0001933414-24-000015-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1933414/000193341424000015/mlys-20240509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001933414-24-000015
- JSON: https://secwatch.observer/filing/0001933414-24-000015.json
- Plain text: https://secwatch.observer/filing/0001933414-24-000015.txt

## Key facts
- Earnings Releases
  Mineralys Therapeutics, Inc. reported the quarter ended March 31, 2024 results: net income $31.5 million.
  - Period: the quarter ended March 31, 2024
  - Net income: $31.5 million
  - Result: reported results
  source text: Net loss was $31.5 million for the quarter ended March 31, 2024, compared to $12.6 million for the quarter ended March 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1933414/000193341424000015/0001933414-24-000015-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.